Justice makes arrests in $2.1B healthcare scheme

Thirty-five defendants have been charged by the Department of Justice in a Medicare fraud case worth more than $2.1 billion. The healthcare fraud case is one of the biggest ever charged.

The case involved fraudulent genetic testing across dozens of telemedicine companies and cancer genetic testing laboratories, charging CEOs, CFOs and others. The DOJ worked with HHS and FBI. CMS’ Center for Program Integrity (CMS/CPI) also announced administrative action against cancer genetic testing companies and medical professionals for $.17 billion in Medicare claims.

The fraud scheme involved illegal kickbacks and bribes by cancer genetic testing labs in exchange for Medicare beneficiary referrals from medical professionals working with fraudulent telemedicine companies. These tests were expensive and medically unnecessary.

In some cases, the tests were “worthless” to the beneficiaries’ doctors or weren’t performed at all, according to the DOJ. Allegedly, hundreds of thousands of elderly and disabled patients were lured into the network by the defendants.

“These defendants allegedly duped Medicare beneficiaries into signing up for unnecessary genetic tests, costing Medicare billions of dollars,” Assistant Attorney General Brian A. Benczkowski of the Justice Department’s Criminal Division said in a statement. “Together with our law enforcement partners, the Department will continue to protect the public fisc and prosecute those who steal our taxpayer dollars.”

The DOJ announced charges against defendants in Florida, Louisiana, Georgia, Texas and New Jersey.

“Unfortunately, audacious schemes such as those alleged in the indictments are pervasive and exploit the promise of new medical technologies such as genetic testing and telemedicine for financial gain, not patient care,” Deputy Inspector General for Investigations Gary L. Cantrell of HHS-OIG, said in a statement.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Trimed Popup
Trimed Popup